Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) remain a management challenge with few reliably effective treatments. Lenalidomide, an immunomodulatory drug approved for patients with myelodysplastic syndrome with del(5q),...
Main Authors: | Helen Ma, Bin Cheng, Francesca Montanari, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Owen A. O’ Connor, Ahmed Sawas |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620720947340 |
Similar Items
-
Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01) -
Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma
by: Kolonic Slobodanka, et al.
Published: (2010-05-01) -
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01) -
TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)